Related Experiment Video
Updated: Sep 1, 2025

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
HIF in Gastric Cancer: Regulation and Therapeutic Target
Mengqing Li1,2, Guan Li3, Xiaodong Yang1
1Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Department of Oncology, Peking University Shenzhen Hospital, Cancer Institute of Shenzhen-PKU-HKUST Medical Center, Shenzhen 518036, China.
Abstract:
HIF means hypoxia-inducible factor gene family, and it could regulate various biological processes, including tumor development. In 2021, the FDA approved the new drug Welireg for targeting HIF-2a, and it is mainly used to treat von Hippel-Lindau syndrome, which demonstrated its good prospects in tumor therapy. As the fourth deadliest cancer worldwide, gastric cancer endangers the health of people all across the world. Currently, there are various treatment methods for patients with gastric cancer, but the five-year survival rate of patients with advanced gastric cancer is still not high. Therefore, here we reviewed the regulatory role and target role of HIF in gastric cancer, and provided some references for the treatment of gastric cancer.
Insights
Hypoxia-inducible factor (HIF) plays a key role in tumor development. This review explores HIF
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- The hypoxia-inducible factor (HIF) gene family regulates critical biological processes, including tumor development.
- Gastric cancer is a leading cause of cancer-related mortality globally, with poor survival rates for advanced stages.
- The FDA-approved drug Welireg targeting HIF-2a for von Hippel-Lindau syndrome highlights the therapeutic potential of HIF inhibition in oncology.
Purpose of the Study:
- To review the regulatory and target roles of HIF in gastric cancer.
- To provide insights into potential HIF-targeted therapies for gastric cancer treatment.
Main Methods:
- Literature review of studies on HIF in gastric cancer.
- Analysis of HIF's involvement in gastric cancer progression and therapeutic strategies.
Main Results:
- HIF is implicated in various aspects of tumor development and progression in gastric cancer.
- Targeting HIF, particularly HIF-2a, shows promise for cancer therapy.
Conclusions:
- HIF represents a significant therapeutic target for gastric cancer.
- Further research into HIF-directed treatments could improve outcomes for advanced gastric cancer patients.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

